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Background: Brucellosis is the most common bacterial zoonosis, and serological tests are routinely used in
brucellosis control and eradication programs. In order to improve the accuracy of serological diagnostic method
used in bovine brucellosis detection, this study developed an improved competitive ELISA with higher specificity
and good sensitivity.
Results: This study prepared 12 monoclonal antibodies against smooth Brucella lipopolysaccharide. One monoclonal
antibody 3 F9, presented C epitope specificity, was used to develop a competitive ELISA for the serological detection
of bovine brucellosis. The competitive ELISA, a commercial competitive ELISA kit, the rose-bengal plate agglutination
test, and a microplate agglutination test were all used in the detection of 6 hyperimmune antisera against
other commonly cross-reacted bacterial pathogens and 110 clinical bovine serum samples. The results of the
test comparisons indicated that the competitive ELISA had higher specificity than the commercial competitive
ELISA kit and RBT, and comparable sensitivity with the commercial ELISA kit.
Conclusions: This study provided a valuable detection tool with high specificity and good sensitivity, which
prevent the wrong-culling of bovines in the eradication campaigns of bovine brucellosis.
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Brucellosis is the most common bacterial zoonosis
caused by members of the Brucella genus, which infect a
wide range of mammals, including dogs, ruminants,
humans, and marine mammals. Within the last few
years, brucellosis has re-emerged, presenting severe
public health challenges and major economic burdens
globally [1]. The measures to eradicate and control brucel-
losis outbreaks are principally based on an intensive test-
and-slaughter policy [2, 3], in which effective technology* Correspondence: wchuanq@163.com; wuqm@cau.edu.cn
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unless otherwise stated.to diagnose brucellosis plays an important role. Although
bacterial isolation and identification of Brucella spp. is
defined as the ‘gold standard’ for diagnosis of brucellosis,
serological tests are routinely used in brucellosis control
and eradication programs. Currently, the common sero-
logical diagnosis methods for bovine brucellosis include
the serum agglutination test (SAT), the rose-bengal plate
agglutination test (RBT), the milk ring test (MRT) [4, 5],
the complement fixation test (CFT) [6], and primary bind-
ing assays such as the indirect ELISA (iELISA) [7, 8], the
competitive ELISA (cELISA) [9, 10], and the fluorescence
polarization assay (FPA) [11]. The majority of serological
tests mentioned rely on the detection of antibodies against
lipopolysaccharide (LPS). However, false positive results
often occur from cross-reaction in the serological detec-
tion [12, 13], due to common antigens on LPS of BrucellaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Coomassie blue-staining (A) and silver-staining (B) of LPS
extracted from B.melitensis 16 M. LPS was prepared by hot
phenol-water extraction method and fractionated by SDS-PAGE
electrophoresis, followed by commassie blue (A) or silver (B) staining.
LPS banding is seen (B). The absence of band in commassie blue
staining as shown in A indicates no contamination of purified LPS with
bacterial proteins. Lane 1: LPS, Lane 2: Molecular weight marker
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and Escherichia coli O157 [14, 15]. The sensitivity and
specificity of different serological tests are variant [16].
Agglutination tests often do not have very good specificity.
The CFT with high specificity and sensitivity has been
approved, but tedious operations make it difficult to use
for large-scale detection. In the past few decades, the FPA
and iELISA with high sensitivity have been used for the
diagnosis of brucellosis. The iELISA methods based on
LPS antigens easily produce cross-reaction with the anti-
bodies against other bacterial pathogens, which may result
in over-culled animals. Unfortunately, the sensitivity of
iELISA with protein antigens is not as good as the sensi-
tivity of iELISA utilizing LPS [17, 18]. The FPA performs
excellently for diagnosis but requires expensive specialized
apparatus for measurement. These faults indicate that a
high-throughput diagnostic methods with good specificity
and sensitivity is necessary. The cELISA has become a
reliable alternate diagnosis for brucellosis. However, of the
limited sensitivity and specificity, the various monoclonal
antibodies (MAbs) used in cELISA may result in omission
or false detection in practical application. Therefore, an
optimal cELISA for the diagnosis of animal brucellosis
should be based on the MAb with high specificity and
satisfactory properties.
LPS is a major surface antigen of Brucella that can be
divided into smooth type (S) or rough type (R) depend-
ing on the inclusion or lack of O-polysaccharide (OPS)
moiety. Four types of epitopes on the Brucella OPS have
been described: the M and A epitopes, present on M
and A dominant Brucella strains, respectively; the com-
mon (C) epitope, strictly specific for smooth Brucella
spp., either A or M dominant; and the C/Y epitope,
which is common to smooth Brucella spp. and Y. entero-
colitica O:9 [19]. Different OPS epitopes are probably
overlapping structures, but the C epitopes would be
important to establish cELISA for the diagnosis of
brucellosis.
For the serological detection of Brucella-infected
cattle, 12 MAbs against smooth Brucella LPS were
produced and characterized. Fortunately, among them,
one was identified to be against C epitope. This MAb
was selected to develop a competitive ELISA, which
was compared with other methods for the detection
of Brucella infection in cattle. The results showed
that the developed cELISA demonstrated significantly
improved specificity and good sensitivity.
Results
Screening and characterization of MAb
This study immunized mice with heat-killed B. melitensis
16 M and boosted with large dose of purified LPS (Fig. 1).
After four times of cell fusion, hybridomas screened by
the iELISA established, twelve positive clones specific toLPS were obtained and then subcloned three times
through the use of a limited dilution method. Among
these MAbs, three were IgG1 (II5G1, 6E3, 4C3), four were
IgG3 (3H7, 3 F9, 2C3, II4D11), four were IgM (6B8, 6 F2,
4H7, I2C10), and one was IgG2a.
Characterization of specificity and epitope of MAb
In this study, the western blot with whole-cell lysates
showed that four MAbs (2C3, 3E3, 3 F9, 6E3) were
specific to B.melitensis 16 M. Meanwhile, the other eight
MAbs (4H7, 4C3, 6B8, 6 F2, II5G1, II4D11, 3H7, I2C10)
recognized epitope C/Y because they had weak cross-
reactivity with Y. enterocolitica O:9 (Fig. 2). The
results from the ELISA were consistent with the west-
ern blot test (Table 1).
Fig. 2 Western blot analysis for specifity of MAbs. Specificity of MAbs was investigated with whole-cell extracts of Brucella melitensis 16 M and
different pathogens. Western blot were carried out as described in Materials and Methods. Abbreviation: Ec: E. coli O157; Pm: P. multocida; Ye: Y.
enterocolitica O:9; Ft: F. tularensis LVS; Bm: B. melitensis 16 M; Oa: O. anthropic ATCC49188; Sg: S. gallinarum
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on the Brucella OPS have been defined, including: A, M,
C (M > A), C (A =M), C/Y (M > A), C/Y (A =M), and C/
Y (A >M) [20, 21]. Further analysis of the MAb epitope
specificity was performed with native rough phenotype
Brucella and with smooth Brucella strains of three
serotypes, i.e., A+M−, A−M+, and A+M+, corresponding
to strains expressing mainly the A (A-dominant) or M
(M-dominant) antigen or both antigens in nearly equiva-




Y. enterocolitica O:9 E. coli
O157
S. gallinarum O.anthropi F.tu
2C3 IgG3 0.043 0.038 0.027 0.035 0.03
3E3 IgG1 0.037 0.053 0.036 0.039 0.03
6E3 IgG1 0.040 0.026 0.023 0.028 0.02
3H7 IgG3 0.350 0.061 0.046 0.045 0.04
3 F9 IgG3 0.037 0.053 0.031 0.042 0.03
4C3 IgG2a 0.422 0.031 0.028 0.033 0.02
II5G1 IgG1 0.434 0.063 0.038 0.048 0.04
II4D11 IgG3 0.557 0.043 0.034 0.041 0.03
6B8 IgM 1.039 0.037 0.030 0.036 0.03
6 F2 IgM 0.959 0.023 0.021 0.033 0.03
4H7 IgM 0.442 0.030 0.028 0.035 0.03
I2C10 IgM 0.503 0.058 0.033 0.040 0.02
aOD of hybridoma supernatants in dilutions of OD 1.0 in iELISA with LPS of B.melite6B8, had no reactivity with rough type B. canis RM 6/66.
MAb 2C3, 3E3, 6E3 reacted only with B. melitensis
16 M ((M-dominant, A−M+), which confirmed the speci-
ficity for M epitope. MAb 3 F9 was thought to be
specific for the C epitope, as it bound to B. melitensis
16 M, B. abortus 2308 (A-dominant, A+M−), and B.
melitensis NI (A+M+).
iELISA was performed to measure the MAbs relative
binding level (Table 1). MAb 3 F9 bound equally to B.
melitensis 16 M and B. melitensis NI, but had a weakerEpitope






0 0.033 0.044 1.176 0.856 0.040 M
1 0.042 0.041 1.419 0.942 0.044 M
5 0.024 0.031 1.086 0.907 0.060 M
3 0.057 0.035 1.115 0.567 1.544 C/Y(A >M)
7 0.049 0.034 1.022 0.983 0.514 C(M > A)
7 0.030 0.043 0.647 0.687 0.605 C/Y(M = A)
1 0.045 0.034 0.906 0.882 1.113 C/Y(M = A)
1 0.042 0.032 0.938 0.930 0.899 C/Y(M = A)
2 0.039 0.205 0.837 0.913 0.991 C/Y(M = A)
1 0.024 0.048 0.897 0.899 0.845 C/Y(M = A)
0 0.034 0.043 0.946 0.853 0.898 C/Y(M = A)
8 0.044 0.040 0.896 0.689 1.317 C/Y(A >M)
nsis 16 M
Fig. 3 Western blot analysis for epitope of MAbs. Whole-cell extracts of B. canis RM6/66 (native rough type), B. melitensis NI (smooth type, A+M+),
B. melitensis 16 M (smooth type, M-dominant, A−M+), B. abortus 2308 (smooth type, A-dominant, A+M−) were used to analyze the epitopic specificity
of MAbs. SDS-PAGE and Western blot were carried out as described in Materials and Methods
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epitope. Aside from binding to Y. enterocolitica O:9, the
binding level of MAbs 4H7, 4C3, 6B8, 6 F2, II5G1, II4D11
were generally equal relative to A or M dominance. These
results confirmed their C/Y (A =M) specificity. As MAb
3H7, I2C10 bound to the A-dominant strain significantly
stronger than to the M-dominant strain, they were
thought to be specific for the C/Y (A >M) epitope.Determination of cut-off value and specificity of cELISA
On account of its specificity for C epitope, MAb 3 F9 was
selected to develop a cELISA. After protocol optimization
of blocking solution, dilution ratio of MAb and sample
respectively, 63 negative bovine serum samples were used
to determine the cut-off value. As the p-value of negative
sera PI analyzed with the Shapiro-Wilk test was 0.482, this
paper concluded that the data were distributed normally.
The mean PI value was 22 % (SD = 9 %) for the bovine.
Therefore, the cut-off value (mean + 2SD) to determine
the status of the serum samples in response to smooth
Brucella was set at 40 % (Fig. 4A).
To confirm its specificity, the cELISA was used to
detect the polyclonal antisera against E. coli O157, S.gallinarum, P. multocida, Y. enterocolitica O:9, F. tularen-
sis LVS, and O. anthropic ATCC49188. The results showed
that the PI values of all of these sera were much lower
than the cut-off value (Fig. 4B).
Comparison among cELISA,a commercial cELISA kit, RBT
and MAT
Six hyperimmune antisera and 110 clinical bovine serum
samples were tested with the cELISA. The resulting data
were compared with data obtained from a commercial
cELISA kit, the RBT and the MAT. Five of the six hyper-
immune antisera were negative in the four diagnostic
tests. Notably, the antisera of Y. enterocolitica O:9
detected as negative in the cELISA and the MAT, but as
positive in the commercial kit and the RBT (Table 2).
Among the bovine sera, the positive rate detected by
the cELISA was 54.5 % (60/110), compared to 48.2 %
(53/110), 62.7 % (69/110), and 42.7 % (47/110) by the
commercial kit, RBT, and MAT, respectively. Data
appear in Table 3, by all four methods, 40 sera were
tested negative and 43 sera tested positive. One sample
tested positive in the commercial kit but negative in the
other three tests. The additional 26 serum samples
tested positive with RBT, and of those sera, 17 were
Fig. 4 Establishment of the cELISA. (A) Percent inhibition values of 63 negative serum samples by cELISA. A cut-off value was set at 40 % (mean +
2SD). (B) Percent inhibition of polyclonal antisera against various bacteria serological related with smooth Brucella. 1 Y. enterocolitica O:9; 2 E. coli O157;
3 S. gallinarum; 4 O. anthropic ATCC49188; 5 F. tularensis LVS; 6 P. multocida; 7 positive bovine sera. Only the positive bovine sera had a PI exceeding
the cut-off value. The Error bars indicate the standard deviations from three-well replications for each serum sample
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cial kit and the MAT missed these positive sera (5 were
missed by both the commercial kit and the MAT, 4 by
just the commercial kit, and 8 by just the MAT). Eight
sera were negative, with the exception of the RBT, and
one was negative in the cELISA and the MAT, but posi-
tive in the commercial kit and RBT. The cELISA agreed
well with the commercial kit (kappa = 0.801), the RBT
(kappa = 0.832), and the MAT (kappa = 0.767). The sup-
plement shows detail detection results of all of the
serum samples (Additional file 1: Table S1).
Discussion
Domestic animals infected with Brucella spp. are culled
partly based on the detection of the antibodies against
Brucella LPS antigen. However, other bacterial infec-
tions often disturb the serological examination of
brucellosis [12, 13], due to the antigens of cross-reaction
among the bacteria. It is known that smooth Brucella LPS
contains O-polysaccharide (OPS) moiety, which has been
divided into seven epitopic specificities: A, M, C (M>A),
C (A =M), C/Y (M>A), C/Y (A =M), and C/Y (A >M)
[20, 21]. Research has shown that the cross-reactions in
the brucellosis serological detection mainly occur as a
result of the similar structures that A and C/Y epitopes
share with the OPS of Y. enterocolitica O:9 and other
bacteria [14, 15]. These possible inaccuracies in serologicalTable 2 Results of 6 hyperimmune antisera detection by cELISA,
commercial kit, RBT and MAT
Sample name cELISA Commercial kit RBT MAT
E. coli O157 - - - -
O. anthropic - - - -
F. tularensis LVS - - - -
S. gallinarum - - - -
Y. enterocolitica O:9 - + + -
P. multocida - - - -
-: negative result, +: positive resultexamination methods due to cross-reaction may result in
the wrong-culling of animals in the campaigns to eradicate
animal brucellosis.
In this study, 12 MAbs against LPS of Brucella meli-
tensis 16 M were characterized, among which four were
IgM MAbs, four were IgG3, three were IgG1, and one
was IgG2a. Brucella strains of three serotypes belonging
to Brucella melitensis and Brucella abortus were used as
representations to identify the epitope specificity of
MAbs. Brucella suis, which possess five biovars of three
serotypes were not used due to the lack of the strains in
the laboratory. As Brucella suis biovar 2 displayed unique
reactivity with MAbs of C (A =M) and C (M>A) [21],
identification of MAbs with Brucella suis biovar 2 may
provide some interesting results. Almost all of the Mabs
were against the C/Y or M epitopes, with the exception of
MAb 3 F9. Interestingly, among the six MAbs that recog-
nized C/Y (A =M) epitope, MAb 6B8 reacted faintly with
B. canis RM 6/66 (Table 1, Fig. 3), which led this study to
analyze whether there were discrepancies between the
epitopes of these MAbs. The ELISA additivity test [23]
was applied to the six MAbs, and the results (see
Additional file 1) showed that either two MAbs failed
to bind simultaneously to the antigen. As the core oligo-
saccharide is common to rough and smooth LPS, MAb
6B8 likely differed from the others by recognizing this
region rather than just the formamido-mannose poly-
mer in OPS [24]. The epitope of MAb 6B8 necessitates
further analysis.
Fortunately, one monoclonal antibody 3 F9, which
belonged to the IgG3 isotype, was identified to be specific
for C epitope as evidenced by western blot and iELISA in
this study. MAb 3 F9 indicates good specificity, as it did
not cross-react with E. coli O157, S. gallinarum, P. multo-
cida, Y. enterocolitica O:9, F. tularensis LVS, or O.
anthropic ATCC49188. Furthermore, the MAb 3 F9 was
used to establish a successful cELISA for the examination
of bovine brucellosis. As Cattle is mainly infected by B.
abortus, sometimes can also be infected by B.melitensis
Table 3 Results of 110 bovine sera samples for Brucella
antibody detection by cELISA, commercial kit, RBT and MAT
Sample number cELISA commercial kit RBT MAT
43 + + + +
40 - - - -
8 + + + -
8 - - + -
5 + - + -
4 + - + +
1 - + + -
1 - + - -
-: negative result, +: positive result
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infected pigs, goats and sheep [25, 26], the method in this
study would be extensively applicable because Brucella C
epitopes appear in all smooth Brucella spp. Besides, this
proposed method could eliminate the nonspecific sero-
logical reaction in the examination of bovine brucellosis.
The established cELISA was compared with RBT,
MAT and a commercial cELISA kit for the detection of
six hyperimmune antisera and 110 clinical bovine serum
samples. The results showed that all of six hyperimmune
antisera, including antisera against E. coli O157 and Y.
enterocolitica O:9 that commonly cross-reacted in brucel-
losis serological diagnosis, presented negative responses in
the cELISA test. However, the hyperimmune antisera
against Y. enterocolitica O:9 tested positive in the com-
mercial kit and RBT. MAT test determined its antibody
titer to be 25. The results demonstrate that the cELISA
established in this study possesses higher specificity than
the commercial cELISA and RBT. Multiple serum samples
from animals infected with these pathogens may be more
suitable for evaluation of the specificity. However, in
consideration of the hyperimmune antisera used in this
test with higher titer and affinity than clinical sera, it’s
persuasive for the good specificity of the cELISA.
The results of 110 clinical bovine sarum samples by
the cELISA coincided with the results of the commercial
kit and RBT at rates of 90 % (99/110), and 91.82 % (101/
110), respectively. All the samples appearing negative in
RBT test also tested negative in the improved cELISA.
Moreover, the samples that had antibody titers over 200
in MAT test also had a positive response in the cELISA,
the commercial kit, and RBT tests. These results shown
in detail in an additional table (see Additional file 2)
suggest that the cELISA has a good detection perform-
ance. Of samples positive in RBT test and of the antibody
titers 50–100 in MAT test, 100 % (23/23) samples tested
positive in the cELISA test, and only 69.6 % (16/23) tested
positive in the commercial cELISA test. These results indi-
cate that the cELISA may have better sensitivity in the de-
tection of serological positive state with low antibody titer.A further accurate comparison may need more serum
samples in status of low antibody titer. These comparative
results also showed that RBT was the most sensitive and
suitable for screening test in bovine brucellosis.
Although this preliminary results indicated the applic-
able prospects of the cELISA for the specific detection
of bovine brucellosis, further evaluating and optimizing
the detection performance of this method was indispens-
able in the future with the standardized positive and
negative sera, and more clinical bovine serum samples.
It was reported that cELISA could be used to distinguish
vaccinated antibody [9, 16]. In this study the ability of
differentiating cattle vaccinated with S19 from infected
with Brucella field strains was also required for evalu-
ation of the detection performance of the cELISA. Some
Brucella-infected animals reacted negatively to sero-
logical tests [27, 28], which indicated an early-stage in-
fection or the bacterial loads were too few. More
research should be conducted on these cases.
Conclusions
This study prepared twelve monoclonal antibodies against
smooth Brucella lipopolysaccharides through cell fusions
and then characterized them by western blot and iELISA.
One monoclonal antibody 3 F9 presented the IgG3
subclass, C epitope specificity. Mab 3 F9 was used to
establish a cELISA for the detection of bovine brucellosis.
A comparison of the cELISA with a commercial cELISA
kit, RBT and MAT showed that, the cELISA had more
specificity than the commercial cELISA kit and RBT, and
comparable sensitivity with the commercial cELISA kit.
This study provided a valuable detection tool with
higher specificity and good sensitivity, which prevent
the wrong-culling of bovines in the eradication cam-
paigns of bovine brucellosis.
Methods
Bacterial strains
The B. abortus 2308, B. melitensis 16 M, and B. canis
RM6/66 were all kindly donated by Qianni He (Institute
of Veterinary Research, Xinjiang Academy of Animal
Sciences, China). These strains were originally collected
and preserved in the China Veterinary Culture Collection
Center (CVCC, Beijing, China). The epidemic strain B.
melitensis NI was isolated from an aborted bovine fetus
from Inner Mongolia by this laboratory. Escherichia coli
O157 and Salmonella gallinarum were preserved in the
laboratory and originally collected in CVCC. Ochrobactrum
anthropic ATCC49188 was purchased from the Guangdong
Microbiology Culture Center. The inactivated culture of
Yersinia enterocolitica O:9 and Francisella tularensis Live
Vaccine Strain were gifts from the Huaiqi Jing (National In-
stitute for Communicable Disease Control and Prevention,
Chinese Center for Disease Control and Prevention, Beijing,
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Beijing, China) respectively. Pasteurella multocida was
isolated from the field and identified in this laboratory
previously. Brucella strains and O. anthropic ATCC49188
were routinely grown in either tryptic soy broth (BD, USA)
or tryptic soy agar. The E. coli O157 and the S. gallinarum
were grown in Luria-Bertani, and the P. multocida was
grown in Brain Heart Infusion Broth (BD, USA). All opera-
tions with living Brucella strains were performed in
biosafety level 3 facilities at China Agricultural University.
Serum samples
Negative bovine serum samples were collected from cat-
tle without a history of Brucella infection. Clinical bo-
vine serum samples were collected from the Beijing and
Hebei provinece in China and stored at −20 °C.
Rabbit hyperimmune antisera against E. coli O157, S.
gallinarum, P. multocida, Y. enterocolitica O:9, F. tular-
ensis LVS, and O. anthropic ATCC49188 were all
prepared previously with immunization with inacti-
vated cultures four times every two weeks. The anti-
sera were used for the specificity analysis of the
established cELISA.
Antigenic preparations
For mice immunization and MAb screening, LPS was
prepared from B. melitensis 16 M by the hot phenol-
water method [29] and then analyzed for purity by
silver-staining and Coomassie Blue Staining [30]. The
Brucella strains were heat-killed at 68 °C for 2 h, and
the other bacteria were inactivated with 0.2 % formalde-
hyde. For MAb specificity and epitope analysis, all the
bacteria were resuspended with PBS and adjusted to OD600
approximately 1.0. For western blot, cell lysates were
obtained by boiling in the presence of SDS. For ELISA,
whole-cell lysates were obtained by ultrasonication.
Establishment of MAb cell lines
Five 4 to 6-week-old female BALB/c mice were
purchased from the Jinmuyang Laboratory Animal
Breeding Co., LTD (Beijing, China). All animal studies
complied with the guidelines for laboratory animal welfare
and ethics set forth by the Beijing Administration Com-
mittee of Laboratory Animals and were approved by the
Animal Care and Use Committee of China Agricultural
University. The mice were immunized with 108 CFU heat-
killed B. melitensis 16 M organisms by intraperitoneal
injection. The mice were boosted with the same dose at
Week 3 and Week 5. Blood was collected from the tail in
order to check the antibody titer, and then the mouse
producing the highest titer was selected for hybridoma
production. Serial boosters using an intraperitoneal injec-
tion of 50 μg of B. melitensis 16 M LPS were given every
day during the three days prior to the cell fusion toimprove the positive rate of antibody secreting hybridoma.
Spleen cells from immunized mice were fused with Sp2/0
mouse myeloma cells at a ratio of 5:1 in the presence of
50 % (w/v) PEG 4000. Then, the fused cells were plated
into 96-well microplates in DMEM with HAT media
supplemented with 20 % fetal bovine serum. The hybrid-
oma cells were cultured in the HAT media for the first
7 days and then in the HT media for the next 7 days. The
culture supernatants were screened for specific antibodies
against LPS by iELISA as described below. The positive
hybridoma clones were subcloned three times by limiting
dilution until monoclones were obtained. The stable
antibody-producing clones were expanded and cryopre-
served in liquid nitrogen. MAb culture supernatants were
produced and collected as described previously [31].
iELISA for screening MAb
The 96-well microplates were coated with LPS (0.5 μg/
ml, 100 μl/well in 0.05 M carbonate buffer, pH 9.6) at 4 °
C overnight. Nonspecific protein binding was blocked
with 5 % skim milk in PBST (0.01 M, pH7.2 PBS
containing 0.05 % Tween-20) at 37 °C for 30 min.
Hybridoma supernatants and HRP-conjugated goat anti-
mouse IgG (KPL, USA) diluted 1:5,000 in PBST were
sequentially added and incubated at 37 °C for 1 h. Sub-
strate solution containing 3,3′,5,5′-tetramethylbenzidine
(TMB) was added to each well at 37 °C for 10 min for
visualization. The reaction was stopped with 2 M
sulfuric acid. An automatic ELISA plate reader (BioTek
synergy ™ 2, USA) was used to measure the absorbance
at 450 nm, and OD above 0.1 was consider positive.
ELISA to determine the isotype of MAb
The isotype of the MAbs were determined by testing the
hybridoma cell culture supernatants with a mouse
monoclonal antibody isotyping kit (SBA, USA), accord-
ing to the manufacturer’s instructions.
Analysis for MAb specificity and epitope
In Western blot, whole-cell extracts of Brucella and other
bacteria were resolved by 12 % SDS-PAGE and then trans-
ferred to a nitrocellulose membrane. The membrane was
blocked with 10 % skim milk at room temperature for 3 h,
then incubated with MAb supernatants at room
temperature for 1 h. Unbounded antibody was washed off,
and then the HRP-conjugated goat anti-mouse IgG was
incubated on the membrane at room temperature for
50 min. Unbound conjugate was then washed off, and the
membrane was added to ECL substrate, placed under an
x-ray film, and exposed in a dark room.
In iELISA, 96-well microplates were incubated at
room temperature overnight with whole-cell lysates
100 μl per well. After blocking, the MAb supernatants
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Establishment of cELISA
The microplates were coated with heat-killed whole-
cell B. melitensis NI cultures in PBS (OD600 approxi-
mately 1.0) 10 μl/well, and then placed in an incubator at
40-50 °C until the liquid completely evaporated. Next, 5 %
glutaraldehyde solution in 0.1 M sodium bicarbonate was
added to fix the antigens and left at room temperature
overnight. After blocking with 5 % skim milk at 37 °C for
1 h, 50 μl of the serum sample 1:20 diluted in blocking
agents was added to each well, followed immediately by
the addition of 50 μl of MAb 3 F9 supernatants 1:400
diluted in blocking agents. The plates were incubated at
37 °C for 1 h with shaking during the initial 3 min. Set
up in duplicate wells, the controls included a strong
positive, a weak positive, a negative control serum, and
a buffer control. After washing with PBST, HRP-
conjugated goat anti-mouse IgG 1:6000 diluted in PBST
was added and incubated at 37 °C for 40 min. The
unbound conjugates were removed by washing, and the
chromogenic reaction was achieved as described above.
As the bottoms of the plates were covered by the
glutaraldehyde solution, two wavelength (450 nm and
630 nm) were used to measure the OD, i.e. OD450-OD630.
The percent inhibition (PI) value was determined using
the formula: PI (%) =100 – (OD [test sample] / OD [buffer
control] × 100).
Sixty-three bovine serum samples from cattle without
a history of Brucella infection, which were previously
confirmed negative through the RBT and a microplate
agglutination test (MAT), were used to determine the PI
cut-off value that was designed as the mean PI of nega-
tive sera + 2 standard deviations (SD), in order to ensure
that 95 % of PI values for the negative sera fell within
this range.
To evaluate its specificity, the cELISA was used to
detect polyclonal antisera against E. coli O157, S. galli-
narum, P. multocida, Y. enterocolitica O:9, F. tularensis
LVS, and O. anthropic ATCC49188. PI for these antisera
were also calculated.
Comparisons of cELISA, a commercial cELISA kit, RBT and
MAT
The 6 polyclonal antisera mentioned above and 110
bovine serum samples were diagnosed using the
cELISA, a commercial cELISA kit (SVANOVIR® Bru-
cella-Ab C-ELISA, Sweden), RBT, and MAT. The
ELISA kit was used in the manner as recommended by
the manufacturer. The RBT was operated as previously
described [22]. The MAT was performed as reported
[32], but with some modification. Serum samples
diluted 1:12.5 and 2-folded serially in the PBS wereprepared in a 96-well V-bottom microplate. An equal
volume (50 μL) of antigen solution was added to each
well. The sealed plates were incubated in a humid
atmosphere at 37 °C for 24 h. The titer of serum
samples was expressed as reciprocal of the highest dilu-
tion of sera showing completely agglutination. The
positive serum samples had titer 100 or more, and the
suspicious serum samples had titer of 50. The smooth
antigens used in the RBT and the MAT were purchased
from the China Institute of Veterinary Drug Control.Statistical analysis
SPSS v20.0 software was used to analyze the result of a
normality test of the negative sera PI values using a
Shapiro-Wilk test. The software was also used to analyze
the degree of agreement between the cELISA, a com-
mercial kit, RBT, and MAT by kappa statistics.Additional files
Additional file 1: Epitope mapping of MAbs (C/Y(M = A)) on
additivity test. The additivity index (AI) value were calculated. The value
below 50 indicated that the MAbs tested recognized the same epitope.
Additional file 2: Detection results of four serological diagnosis.
The detail detection results of 110 bovine sera samples and 6 hyperimmune
antisera in four serological diagnosis were shown in the table.
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